NO330813B1 - Fremgangsmate for a analysere en heterolog nukleinsyrepopulasjon - Google Patents
Fremgangsmate for a analysere en heterolog nukleinsyrepopulasjon Download PDFInfo
- Publication number
- NO330813B1 NO330813B1 NO20015635A NO20015635A NO330813B1 NO 330813 B1 NO330813 B1 NO 330813B1 NO 20015635 A NO20015635 A NO 20015635A NO 20015635 A NO20015635 A NO 20015635A NO 330813 B1 NO330813 B1 NO 330813B1
- Authority
- NO
- Norway
- Prior art keywords
- nucleic acid
- acid molecules
- dna
- sequences
- microarray
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 123
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 99
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title claims abstract description 86
- 238000002493 microarray Methods 0.000 claims abstract description 68
- 239000000523 sample Substances 0.000 claims description 116
- 238000009396 hybridization Methods 0.000 claims description 43
- 239000002299 complementary DNA Substances 0.000 claims description 42
- 238000012163 sequencing technique Methods 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 9
- 239000011521 glass Substances 0.000 claims description 8
- 230000002285 radioactive effect Effects 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 42
- 108020004999 messenger RNA Proteins 0.000 abstract description 39
- 238000010367 cloning Methods 0.000 abstract description 6
- 230000003252 repetitive effect Effects 0.000 abstract description 4
- 230000008030 elimination Effects 0.000 abstract description 2
- 238000003379 elimination reaction Methods 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 58
- 108020004635 Complementary DNA Proteins 0.000 description 47
- 239000012634 fragment Substances 0.000 description 42
- 238000010804 cDNA synthesis Methods 0.000 description 41
- 238000003752 polymerase chain reaction Methods 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000010276 construction Methods 0.000 description 14
- 238000002955 isolation Methods 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 230000003100 immobilizing effect Effects 0.000 description 9
- 108091060211 Expressed sequence tag Proteins 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 238000001712 DNA sequencing Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000276498 Pollachius virens Species 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108020005196 Mitochondrial DNA Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000003365 glass fiber Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000009274 differential gene expression Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011410 subtraction method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- RFRSCTPKEGYARM-UHFFFAOYSA-N 3-(3-hydroxy-6-oxoxanthen-9-yl)propanoic acid Chemical class O=C1C=CC2=C(CCC(=O)O)C3=CC=C(O)C=C3OC2=C1 RFRSCTPKEGYARM-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091028733 RNTP Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 150000001893 coumarin derivatives Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Ceramic Products (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/314,698 US6638717B2 (en) | 1999-05-19 | 1999-05-19 | Microarray-based subtractive hybridzation |
| PCT/US2000/013789 WO2000070098A1 (en) | 1999-05-19 | 2000-05-19 | Microarray-based subtractive hybridization |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20015635D0 NO20015635D0 (no) | 2001-11-19 |
| NO20015635L NO20015635L (no) | 2002-01-15 |
| NO330813B1 true NO330813B1 (no) | 2011-07-25 |
Family
ID=23221053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20015635A NO330813B1 (no) | 1999-05-19 | 2001-11-19 | Fremgangsmate for a analysere en heterolog nukleinsyrepopulasjon |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6638717B2 (ko) |
| EP (1) | EP1185699B1 (ko) |
| JP (1) | JP4714883B2 (ko) |
| KR (1) | KR100733930B1 (ko) |
| AT (1) | ATE382097T1 (ko) |
| AU (1) | AU779901B2 (ko) |
| BR (1) | BR0011297A (ko) |
| CA (1) | CA2372698C (ko) |
| CY (1) | CY1107428T1 (ko) |
| DE (1) | DE60037584T2 (ko) |
| DK (1) | DK1185699T3 (ko) |
| ES (1) | ES2296623T3 (ko) |
| IL (2) | IL146547A0 (ko) |
| MX (1) | MXPA01011730A (ko) |
| NO (1) | NO330813B1 (ko) |
| PT (1) | PT1185699E (ko) |
| WO (1) | WO2000070098A1 (ko) |
| ZA (1) | ZA200109609B (ko) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050272056A1 (en) * | 1996-11-13 | 2005-12-08 | Deiss Louis P | Gene identification method |
| US20020142341A1 (en) * | 2001-03-28 | 2002-10-03 | Makoto Kameyama | Method and apparatus for producing probe carrier |
| US20040110153A1 (en) * | 2002-12-10 | 2004-06-10 | Affymetrix, Inc. | Compleixity management of genomic DNA by semi-specific amplification |
| JP4182338B2 (ja) * | 2003-03-06 | 2008-11-19 | 信越化学工業株式会社 | 熱硬化性パーフルオロポリエーテル系ゴム組成物及びゴム製品 |
| US7300755B1 (en) * | 2003-05-12 | 2007-11-27 | Fred Hutchinson Cancer Research Center | Methods for haplotyping genomic DNA |
| US7044966B2 (en) | 2003-10-06 | 2006-05-16 | 3F Therapeutics, Inc. | Minimally invasive valve replacement system |
| EP1771563A2 (en) | 2004-05-28 | 2007-04-11 | Ambion, Inc. | METHODS AND COMPOSITIONS INVOLVING MicroRNA |
| ES2534304T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| CA2663962A1 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
| EP2487240B1 (en) | 2006-09-19 | 2016-11-16 | Interpace Diagnostics, LLC | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| GB0618514D0 (en) * | 2006-09-20 | 2006-11-01 | Univ Nottingham Trent | Method of detecting interactions on a microarray using nuclear magnetic resonance |
| US8716190B2 (en) | 2007-09-14 | 2014-05-06 | Affymetrix, Inc. | Amplification and analysis of selected targets on solid supports |
| US9388457B2 (en) | 2007-09-14 | 2016-07-12 | Affymetrix, Inc. | Locus specific amplification using array probes |
| EP2990487A1 (en) | 2008-05-08 | 2016-03-02 | Asuragen, INC. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
| JP5221248B2 (ja) * | 2008-08-26 | 2013-06-26 | 株式会社日立ハイテクノロジーズ | 高発現遺伝子由来のｃＤＮＡクローンの含有率を低減させたｃＤＮＡライブラリーの作製方法 |
| US20100331204A1 (en) * | 2009-02-13 | 2010-12-30 | Jeff Jeddeloh | Methods and systems for enrichment of target genomic sequences |
| US20110059453A1 (en) * | 2009-08-23 | 2011-03-10 | Affymetrix, Inc. | Poly(A) Tail Length Measurement by PCR |
| EP2542678B1 (en) | 2010-03-04 | 2017-04-12 | InteRNA Technologies B.V. | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT |
| CA2804599C (en) | 2010-07-06 | 2023-01-31 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| EP2640851A2 (en) | 2010-11-17 | 2013-09-25 | Asuragen, Inc. | Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms |
| EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| EP2681566A2 (en) | 2011-02-28 | 2014-01-08 | University of Iowa Research Foundation | Anti-müllerian hormone changes in pregnancy and prediction ofadverse pregnancy outcomes and gender |
| MX2013012709A (es) | 2011-05-02 | 2013-12-06 | Pioneer Hi Bred Int | Estrategia de analisis de arnm bacteriano para descubrir nuevas moleculas de acido nucleico codificante de pesticidas. |
| WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
| US20130157884A1 (en) | 2011-10-26 | 2013-06-20 | Asuragen, Inc. | Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts |
| EP2771487A1 (en) | 2011-10-27 | 2014-09-03 | Asuragen, INC. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
| US20150152499A1 (en) | 2012-07-03 | 2015-06-04 | Interna Technologies B.V. | Diagnostic portfolio and its uses |
| US20140100124A1 (en) | 2012-10-04 | 2014-04-10 | Asuragen, Inc. | Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions |
| EP2971132B1 (en) | 2013-03-15 | 2020-05-06 | Baylor Research Institute | Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer |
| EP2971149B1 (en) | 2013-03-15 | 2018-05-09 | Baylor Research Institute | Ulcerative colitis (uc)-associated colorectal neoplasia markers |
| EP3404116B1 (en) | 2013-03-15 | 2022-10-19 | The University of Chicago | Methods and compositions related to t-cell activity |
| KR101516976B1 (ko) * | 2013-10-30 | 2015-05-04 | 에스케이텔레콤 주식회사 | 표적 염기 서열 해독에서의 바이어스 제거 방법 |
| AU2018358016A1 (en) | 2017-11-03 | 2020-05-07 | Interna Technologies B.V. | MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
| JP7566775B2 (ja) | 2019-04-12 | 2024-10-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 筋肉量及び酸化的代謝を増加させるための組成物及び方法 |
| WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5821058A (en) | 1984-01-16 | 1998-10-13 | California Institute Of Technology | Automated DNA sequencing technique |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5591575A (en) | 1993-04-07 | 1997-01-07 | Amersham International Plc | Subtraction hybridization employing aziridinylbenoquinone cross-linking agents |
| US5482845A (en) | 1993-09-24 | 1996-01-09 | The Trustees Of Columbia University In The City Of New York | Method for construction of normalized cDNA libraries |
| US5690894A (en) * | 1995-05-23 | 1997-11-25 | The Regents Of The University Of California | High density array fabrication and readout method for a fiber optic biosensor |
| US5728529A (en) | 1995-06-23 | 1998-03-17 | Baylor College Of Medicine | Alternative dye-labeled ribonucleotides, deoxyribonucleotides, and dideoxyribonucleotides for automated DNA analysis |
| US5851772A (en) | 1996-01-29 | 1998-12-22 | University Of Chicago | Microchip method for the enrichment of specific DNA sequences |
| US5712127A (en) | 1996-04-29 | 1998-01-27 | Genescape Inc. | Subtractive amplification |
| US5827658A (en) | 1996-08-09 | 1998-10-27 | The United States Of America As Reprsented By The Department Of Health And Human Services | Isolation of amplified genes via cDNA subtractive hybridization |
| GB9618050D0 (en) | 1996-08-29 | 1996-10-09 | Cancer Res Campaign Tech | Global amplification of nucleic acids |
| US5846721A (en) | 1996-09-19 | 1998-12-08 | The Trustees Of Columbia University In The City Of New York | Efficient and simpler method to construct normalized cDNA libraries with improved representations of full-length cDNAs |
| US5953727A (en) * | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
| JP2002507275A (ja) | 1997-03-24 | 2002-03-05 | スミスクライン・ビーチャム・コーポレイション | 引き算ライブラリーの製造方法 |
| US6399334B1 (en) | 1997-09-24 | 2002-06-04 | Invitrogen Corporation | Normalized nucleic acid libraries and methods of production thereof |
| AU753505B2 (en) | 1997-10-30 | 2002-10-17 | Cold Spring Harbor Laboratory | Probe arrays and methods of using probe arrays for distinguishing DNA |
| US5882874A (en) | 1998-02-27 | 1999-03-16 | The Trustees Of Columbia University In The City Of New York | Reciprocal subtraction differential display |
-
1999
- 1999-05-19 US US09/314,698 patent/US6638717B2/en not_active Expired - Lifetime
-
2000
- 2000-05-19 JP JP2000618503A patent/JP4714883B2/ja not_active Expired - Fee Related
- 2000-05-19 WO PCT/US2000/013789 patent/WO2000070098A1/en active IP Right Grant
- 2000-05-19 PT PT00936091T patent/PT1185699E/pt unknown
- 2000-05-19 KR KR1020017014682A patent/KR100733930B1/ko not_active IP Right Cessation
- 2000-05-19 IL IL14654700A patent/IL146547A0/xx active IP Right Grant
- 2000-05-19 AT AT00936091T patent/ATE382097T1/de active
- 2000-05-19 EP EP00936091A patent/EP1185699B1/en not_active Expired - Lifetime
- 2000-05-19 MX MXPA01011730A patent/MXPA01011730A/es active IP Right Grant
- 2000-05-19 DK DK00936091T patent/DK1185699T3/da active
- 2000-05-19 AU AU51455/00A patent/AU779901B2/en not_active Ceased
- 2000-05-19 BR BR0011297-6A patent/BR0011297A/pt not_active IP Right Cessation
- 2000-05-19 CA CA2372698A patent/CA2372698C/en not_active Expired - Fee Related
- 2000-05-19 DE DE60037584T patent/DE60037584T2/de not_active Expired - Lifetime
- 2000-05-19 ES ES00936091T patent/ES2296623T3/es not_active Expired - Lifetime
-
2001
- 2001-11-18 IL IL146547A patent/IL146547A/en not_active IP Right Cessation
- 2001-11-19 NO NO20015635A patent/NO330813B1/no not_active IP Right Cessation
- 2001-11-21 ZA ZA200109609A patent/ZA200109609B/xx unknown
-
2008
- 2008-03-07 CY CY20081100274T patent/CY1107428T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200109609B (en) | 2003-04-30 |
| KR100733930B1 (ko) | 2007-07-03 |
| CA2372698A1 (en) | 2000-11-23 |
| EP1185699B1 (en) | 2007-12-26 |
| DE60037584D1 (de) | 2008-02-07 |
| US20020051970A1 (en) | 2002-05-02 |
| WO2000070098A1 (en) | 2000-11-23 |
| PT1185699E (pt) | 2008-02-26 |
| EP1185699A1 (en) | 2002-03-13 |
| MXPA01011730A (es) | 2002-04-24 |
| DE60037584T2 (de) | 2009-01-08 |
| US6638717B2 (en) | 2003-10-28 |
| BR0011297A (pt) | 2002-02-26 |
| CY1107428T1 (el) | 2012-12-19 |
| CA2372698C (en) | 2010-04-27 |
| AU5145500A (en) | 2000-12-05 |
| JP4714883B2 (ja) | 2011-06-29 |
| IL146547A0 (en) | 2002-07-25 |
| ATE382097T1 (de) | 2008-01-15 |
| IL146547A (en) | 2008-04-13 |
| NO20015635D0 (no) | 2001-11-19 |
| JP2002543856A (ja) | 2002-12-24 |
| AU779901B2 (en) | 2005-02-17 |
| ES2296623T3 (es) | 2008-05-01 |
| NO20015635L (no) | 2002-01-15 |
| KR20020008190A (ko) | 2002-01-29 |
| DK1185699T3 (da) | 2008-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO330813B1 (no) | Fremgangsmate for a analysere en heterolog nukleinsyrepopulasjon | |
| US6156502A (en) | Arbitrary sequence oligonucleotide fingerprinting | |
| JP2976406B2 (ja) | 核酸プローブ | |
| AU606043B2 (en) | Detection of viruses by amplification and hybridization | |
| US20230340590A1 (en) | Method for verifying bioassay samples | |
| EP0701001A2 (en) | DNA separating, fractionating and analyzing method and system therefor | |
| US20030087298A1 (en) | Detection of hybridization on oligonucleotide microarray through covalently labeling microarray probe | |
| JP2002501760A (ja) | 核酸解析方法 | |
| JP2003502059A (ja) | ゲノムプロファイリング：多種生物の存在について複雑な生物学的試料を試験するための迅速な方法 | |
| EP2971139A2 (en) | Systems and methods for detection of genomic copy number changes | |
| WO2004022758A1 (en) | Genome partitioning | |
| JPH09289900A (ja) | 核酸配列（β２．７）を利用したサイトメガロウイルス（ＣＭＶ）の核酸増幅ならびに検出用試薬キット | |
| US20060228714A1 (en) | Nucleic acid representations utilizing type IIB restriction endonuclease cleavage products | |
| WO2019212138A1 (ko) | 차세대 염기서열 분석을 위한 시료 간 교차 오염 탐색용 내부 검정 물질 | |
| US6759195B1 (en) | Method of differential display of prokaryotic messenger RNA by RTPCR | |
| US20060172289A1 (en) | Combinatorial oligonucleotide pcr | |
| RU2787079C1 (ru) | Деплеция рнк на основе нуклеазы | |
| Hilborne et al. | Diagnostic applications of recombinant nucleic acid technology: basic techniques | |
| Mahajan et al. | Molecular Techniques for Diagnosis of Systemic Fungal Infections | |
| Ganova-Raeva | Artificial Nucleic Acids and Genome Profiling | |
| SCHMIDT¹ et al. | Phylogenetic Identification of Uncultivated Microorganisms in Natural Habitats TM SCHMIDT¹, EF DELONG², and NR PACE¹ | |
| JP2005065604A (ja) | 魚病細菌検出基板、魚病細菌検出方法、および、魚病細菌検出試薬 | |
| IL102382A (en) | Method for detecting nucleotide sequences and test kit therefor | |
| JPH06103302B2 (ja) | 成人ｔ細胞白血病診断薬 | |
| AU2001297868A1 (en) | Partially double-stranded nucleic acids, methods of making, and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |